![]() New York, (GLOBE NEWSWIRE) - announces the release of the report "Cardiovascular Medical Lasers Global Market Report 2022" - ġ0 billion in 2021 to $0.15 billion in 2022 at a compound annual growth rate (CAGR) of 44.3%. The global cardiovascular medical lasers market is expected to grow from $0. The company operates through two segments - Chronic Care and Pain Management.Major players in the cardiovascular medical lasers market are Boston Scientific Corp, Cardiovascular Systems, AngioDynamics, Royal Philips NV, and RA Medical Systems. The company’s product suite includes the CyberKnife Systems and the TomoTherapy Systems.Īvanos Medical is a medical technology company that offers infection prevention, surgical, respiratory, digestive health and pain management solutions. The company’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.Īccuray designs, develops, and sells radiosurgery and radiation therapy systems for treatment of tumors in the body. ![]() AVNS.Ībiomed is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. ABMD, Accuray Incorporated ARAY and Avanos Medical, Inc. Some other key players in the medical instruments space are Abiomed, Inc. The growing need for medical lasers for the treatment of several diseases and rising demand for non-invasive treatments are some of the factors fueling the medical lasers market growth. Per a report by Fortune Business Insights, the global medical lasers market size (valued at $3.79 billion) is anticipated to reach $12.33 billion by 2026 at a CAGR of 15.9% from the current year. Notably, the buyouts of BioSentry and RadiaDyne have proven to be accretive for AngioDynamics’ Oncology business in recent times. It is expected to aid AngioDynamics radiation portfolio. The company recently concluded its acquisition of RadiaDyne, a privately held medical diagnostic and device company with two different product lines. Per management, strong growth in AngioVac and Thrombolytic product line drove revenues.ĪngioDynamics continues to expand presence on the back of acquisitions and strategic alliances. Speaking of the expansion of AngioDyanamics’ VIT product portfolio, in the fiscal first-quarter 2020, VIT revenues grossed $28.9 million, up 1.1% from the prior-year quarter’s figure. Interestingly, this proprietary technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies. The transaction is being funded exclusively in cash.Įximo’s excellent and foundational technology will enhance AngioDyanamic’s portfolio, which will change the way patients with PAD receive treatment.įurther, the buyout will enable AngioDyanmics to foray into a growing and lucrative market (valued at more than $500 million) with an innovative medical solution providing much more versatility, broad array of treatments and robust clinical data to support its efficiency. Notably, this technology is the only system that has the ability to deliver short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures.ĪngioDynamics made the acquisition with $46 million in up-front consideration, with up to $20 million of contingent consideration related to certain technical and revenue milestones. The technology is a significant breakthrough among medical devices used in atherectomy procedures to treat PAD currently. ![]() Notably, Eximo’s proprietary laser technology will ably complement AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio.įor investors’ notice, Eximo’s proprietary laser technology has received 510 (k) clearance with respect to the treatment of Peripheral Artery Disease (PAD). ![]() – an early commercial stage medical device company – and its proprietary 355nm wavelength laser-technology platform. ANGO recently acquired Eximo Medical Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |